Tower Research Capital (TRC)’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-10,834
| Closed | -$4.01K | – | 6413 |
|
|
2023
Q3 | $4.01K | Buy |
10,834
+276
| +3% | +$158 | ﹤0.01% | 4932 |
|
|
2023
Q2 | $12.4K | Buy |
10,558
+9,010
| +582% | +$8.61K | ﹤0.01% | 3879 |
|
|
2023
Q1 | $3K | Buy |
1,548
+1,247
| +414% | +$3.17K | ﹤0.01% | 5298 |
|
|
2022
Q4 | $1K | Buy |
301
+137
| +84% | +$820 | ﹤0.01% | 5813 |
|
|
2022
Q3 | $2K | Sell |
164
-12
| -7% | -$279 | ﹤0.01% | 5717 |
|
|
2022
Q2 | $6K | Buy |
176
+112
| +175% | +$5.24K | ﹤0.01% | 5021 |
|
|
2022
Q1 | $4K | Buy |
64
+28
| +78% | +$5.17K | ﹤0.01% | 5334 |
|
|
2021
Q4 | $11K | Buy |
36
+23
| +177% | +$14.4K | ﹤0.01% | 4524 |
|
|
2021
Q3 | $10K | Buy |
+13
| New | +$11.3K | ﹤0.01% | 4392 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 6182 |
|
|
2021
Q1 | – | Sell |
-1
| Closed | -$2K | – | 5946 |
|
|
2020
Q4 | $1K | Buy |
+1
| New | +$2.05K | ﹤0.01% | 5078 |
|
|
2020
Q3 | – | Sell |
-1
| Closed | -$6K | – | 5259 |
|
|
2020
Q2 | $6K | Sell |
1
-1
| -50% | -$4.8K | ﹤0.01% | 4247 |
|
|
2020
Q1 | $8K | Buy |
2
+1
| +100% | +$9.44K | ﹤0.01% | 2154 |
|
|
2019
Q4 | $6K | Buy |
+1
| New | +$8.53K | ﹤0.01% | 2648 |
|
Tower Research Capital (TRC)'s BXRX Position: Q4 2023 in Review
Tower Research Capital (TRC) sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2023, closing a stake of 10,834 shares — an estimated $4.01K sold.
Tower Research Capital (TRC) first reported a position in BXRX in Q4 2019 and held it in 13 quarters. The position peaked at $12.4K in Q2 2023. 2 funds tracked by Wall St. Rank hold BXRX as of Q4 2023.
- Tower Research Capital (TRC) reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 10,834 Baudax Bio, Inc. Common Stock shares in Q4 2023, an estimated $4.01K.
- Tower Research Capital (TRC) first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 13 quarters.
- Tower Research Capital (TRC)'s Baudax Bio, Inc. Common Stock position peaked at $12.4K in Q2 2023.
- 2 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.